Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994459 · ClinicalTrials.gov registry record
Study of Fat Tissue's Ability to Take up Sugar in the Obese Population
A clinical trial of Glucose Metabolism Disorders, sponsored by University of Missouri-Columbia.
- Active
- Registry status
- 90
- Enrollment target
- 1
- Study location
NCT02994459: Active study of Glucose Metabolism Disorders, sponsored by University of Missouri-Columbia.
NCT02994459 is a study of Glucose Metabolism Disorders that is active but no longer recruiting, run by University of Missouri-Columbia. The registered enrollment target is 90 participants, below the 224-participant average among 14 other Glucose Metabolism Disorders trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02994459, a study of Glucose Metabolism Disorders, is active but no longer recruiting, sponsored by University of Missouri-Columbia.
- ACTIVE NOT RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
People who are obese often have insulin resistance (inability of insulin to properly control blood sugar) and high blood sugar. However, not all people with obesity have this problem. About one-third of people with obesity have normal sugar metabolism (the way your body uses sugar). Similarly, not all people who are lean are also metabolically healthy and a subset of people who are lean are referred to as metabolically abnormal lean (MAL) or metabolically obese lean because they have the abnormalities in glucose metabolism typically associated with obesity. The reasons why some people with obesity have a problem with blood sugar control and others do not are not entirely clear. It is thought that impaired muscle sugar uptake is the main problem related to high blood sugar in people with obesity. However, adipose tissue (fat tissue) also consumes a substantial amount of blood sugar. Therefore, it is unclear whether muscle or adipose tissue (fat tissue) are primarily responsible for altered blood sugar concentrations in persons with metabolically abnormal obesity (MAO) (those with insulin resistance), compared to those with metabolically normal (healthy) obesity (MNO), or whether "healthy" adipose tissue (fat tissue) expansion in MNO people compared with lean people provides a vessel for blood sugar removal that helps maintain normal blood sugar concentration. Accordingly, the investigators will determine the amount of sugar that is taken up by the body and in the cells of adipose tissue (fat tissue) and muscle by infusing labeled sugar into the blood and looking at its disappearance from blood and appearance in adipose tissue (fat tissue) and muscle. The investigators will also determine how well insulin, a hormone that controls blood sugar, turns on signals that stimulate sugar uptake in fat and muscle cells. These studies will be done after an overnight fast and during an infusion of sugar and insulin (hyperinsulinemic-euglycemic clamp), in sex- and age-matched pe
Primary Outcome
Comparison of whole body and total adipose tissue glucose disposal rate assessed by using stable isotope labeled glucose tracer infusion in conjunction with dynamic PET imaging
Conditions Studied
Interventions
- OTHER Weight Loss
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2027-01 |
What the registry record for NCT02994459 still lists
NCT02994459 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 224-participant average among 14 other Glucose Metabolism Disorders trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Glucose Metabolism Disorders appearing as the primary indexed condition, and to 1 intervention - of which Weight Loss is the first listed.
NCT02994459 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT02994459 about?
NCT02994459 is a clinical study titled "Study of Fat Tissue's Ability to Take up Sugar in the Obese Population". People who are obese often have insulin resistance (inability of insulin to properly control blood sugar) and high blood sugar. However, not all people with obesity have this problem. About one-third of people with obesity have normal sugar metabolism (the way your body uses sugar). Similarly, not a...
What is the current status of trial NCT02994459?
This trial is currently active not recruiting. The enrollment target is 90 participants. The study started on 2017-07-01. Estimated completion is 2027-01.
What conditions does trial NCT02994459 study?
This clinical trial studies the following conditions: Glucose Metabolism Disorders.
What interventions are being tested in trial NCT02994459?
The interventions under investigation include: Weight Loss (OTHER).
Who is sponsoring clinical trial NCT02994459?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02994459 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glucose Metabolism Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02994459's enrollment target sits among peer trials
90 7th of 14 higher than 8 of 14 other Glucose Metabolism Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glucose Metabolism Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Animal and Plant Proteins and Glucose Metabolism
RECRUITING · NA
-
Rare and Atypical Diabetes Network
RECRUITING
-
Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes
RECRUITING · Phase 2
-
Brain Metabolism Observed at 7 Tesla
RECRUITING
-
Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes
RECRUITING · NA
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI